Continuous monitoring and measurements. Advanced clinical insight.

Philips IntelliVue with
Masimo rainbow SET™

Philips patient monitoring with Masimo technology provides noninvasive, continuous hemoglobin monitoring you can rely on – at the point of care. Maintain consistent visibility on your patient's condition between invasive hemoglobin samples. Streamline workflows and drive down costs while providing clinically proven patient monitoring across care settings.

Learn about the Philips and Masimo partnership

Request information

Measure value with Masimo technology

Philips lntelliVue with Masimo rainbow SET expands clinical capabilities without burdening operations.

Provides accurate hemoglobin measurement

Stay informed about changes in your patient's hemoglobin - in between invasive blood samples.

Works with your IT

Capture additional continuous data and feed it securely to the EMR via existing infrastructure.

Supports your hospital's workflows

View trends, key measurement parameters and more, at the bedside and during transport.

Noninvasive measurement technology – in clinical practice

Peer reviews have found that using SpHb® monitoring in conjunction with invasive blood sampling can deliver value in the ER, OR, and beyond.

In low blood loss surgical applications

Reduces unnecessary transfusions

>87% reduction in transfusion frequency

(from 4.5% to 0.6%)¹

>90% reduction in average units transfused (from 0.1 to 0.01 units per patient)¹

In high blood loss surgical applications

Reduces unnecessary transfusions

> 73% to 32% reduction in the percentage of patients receiving 3 or more units^2*

> 47% reduction in average units transfused (1.9 to 1.0 per patient)^2*

Initiate timely transfusions when transfusions are needed

Learn more about Masimo rainbow SET technology

How can we help you?

Contact information

* This field is mandatory

Country

First name*

First name (phonetic)

Last name*

Last name (phonetic)

Salutation

Academic title

Email address*

Business phone number (ex. +971 2 123 4567)

Company*

Job title

Industry

Function

Specialty

Department

State or Province

City

Address

Zip or Postal Code

By specifying your reason for contact we will be able to provide you with a better service.

We work with partners and distributors who may contact you about this Philips product on our behalf.

Follow up information

Preferred method of contact

Best time to call

Estimated time of purchase

Kindly enter your comments regarding the inquiry

I hereby consent to processing of my personal data and sensitive personal data (if any) and transfer of such data abroad, in accordance with the Privacy Notice that can be found here.

What is cross border data transfer?

I agree on cross-border transfer of personal information.

I hereby agree to receive by email or telephone information about Philips products, services, events and promotions, including information by mail that is appropriate to me, taking into account my activities and preferences, including the Expectations I have indicated / and in this form.

I agree that Philips may share my personal information with authorized resellers of its Philips products and equipment in order to meet my expectations as stated in this form.

I would like to receive marketing related electronic communications about Philips products, services, events, and promotions that may be relevant to me based on my user preferences and behavior. I can revoke my consent at any time.

Final CEE consent

Read more about Philips and Masimo

The partnership

Philips and Masimo have teamed up to create the future of measurements and monitoring.

rainbow SET measurement technology

Continuous visibility of key patient measurement parameters.

References

Masimo clinical claims are referenced on this web page. All studies available at www.masimo.com/evidence/featured-studies/feature/

(1) Transt . 2014. 5:237.DOl:10.4172/2155-9864.1000237

(2) Awada WN et al J Clin Mon it Comput. DOI 10.1007/s10877-015-9660-4.

^*Study Protocol: In each group, if researchers noted SpHb trended downward below 10 g/dl, a red blood cell transfusion was started and continued until SpHb** trended upward above 10 g/dl. The transfusion threshold of 10 g/dl was predetermined by the study protocol and may not be appropriate for all patients. Blood sampling was the same for the control and test group. Arterial blood was drawn from a 20 gauge radial. **SpHb monitoring is not intended to replace lab testing. Blood samples should be analyzed by lab instruments prior to clinical decision making.